Gary R. Conte
Vertrieb & Marketing bei Three Rivers Pharmaceuticals LLC
Profil
Gary R.
Conte is Vice President of Sales for Three Rivers Pharmaceuticals LLC.
Prior to joining Three Rivers Pharmaceuticals, he was Vice President of Sales East Region for Fisher Investments, East Area Business Director for Guilford Pharmaceuticals, as well as Regional Manager and Strategic Business Manager for Sequus Pharmaceuticals.
Previously, Mr. Conte was Director of Pain Care Sales and Senior Director of Strategic Healthcare for Cephalon, Inc. and Corporate Account Director for Oncology Rhone Poulenc Rorer.
He received a BS degree in Business Administration from Duquesne University.
Aktive Positionen von Gary R. Conte
| Unternehmen | Position | Beginn |
|---|---|---|
Three Rivers Pharmaceuticals LLC
 Three Rivers Pharmaceuticals LLC Pharmaceuticals: MajorHealth Technology Three Rivers Pharmaceuticals LLC develops, manufactures, and markets pharmaceutical therapies. Its medicines include Amphotec/Amphocil and Ribasphere for use in combination with interferon alfa-2b in the US. The firm was founded by Donald J. Kerrish, Paul F. Fagan, and Patrick L. Kerrish in April, 2000 and is headquartered in Cranberry Township, PA. | Vertrieb & Marketing | - |
Ehemalige bekannte Positionen von Gary R. Conte
| Unternehmen | Position | Ende |
|---|---|---|
SEQUUS Pharmaceuticals, Inc.
 SEQUUS Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology SEQUUS Pharmaceuticals, Inc. is based in Menlo Park, CA. Part of Johnson & Johnson, SEQUUS Pharmaceuticals, Inc. is a company that markets lipid-based biopharmaceutical products mainly to treat cancer and infectious diseases. SEQUUS Pharmaceuticals was acquired by ALZA Corp., part of Johnson & Johnson from June 22, 2001 on March 16, 1999 for $658.03 million. | Corporate Officer/Principal | - |
Cephalon, Inc.
 Cephalon, Inc. Pharmaceuticals: MajorHealth Technology Cephalon, Inc. manufactures and distributes pharmaceutical products. It engages in the discovery and development of medicines for central nervous system disorders, pain, and cancer. The company was founded on August 24, 1987 by Frank Baldino, Jr. and is headquartered in Frazer, PA. | Corporate Officer/Principal | 17.08.2011 |
Guilford Pharmaceuticals, Inc.
 Guilford Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Guilford Pharmaceuticals Inc. is a pharmaceutical company engaged in the research, development and commercialization of proprietary drugs that target the hospital and neurology markets. Presently, Guilford markets two commercial products, GLIADEL(R) Wafer, for the treatment of brain cancer, and AGGRASTAT(R) Injection, a glycoprotein GP IIb/IIIa receptor antagonist for the treatment of acute coronary syndrome (ACS). Guilford's product pipeline includes a novel anesthetic, AQUAVAN(R) Injection, and drugs for treating Parkinson's disease and peripheral nerve injury | Corporate Officer/Principal | - |
Ausbildung von Gary R. Conte
| Duquesne University of The Holy Spirit | Undergraduate Degree |
Erfahrungen
Besetzte Positionen
Aktive
Inaktive
Börsennotierte Unternehmen
Private Unternehmen
Beziehungen
Beziehungen ersten Grades
Unternehmen ersten Grades
Herr
Frau
Aufsichtsräte
Führungskräfte
Unternehmensverbindungen
| Private Unternehmen | 4 |
|---|---|
Three Rivers Pharmaceuticals LLC
Three Rivers Pharmaceuticals LLC Pharmaceuticals: MajorHealth Technology Three Rivers Pharmaceuticals LLC develops, manufactures, and markets pharmaceutical therapies. Its medicines include Amphotec/Amphocil and Ribasphere for use in combination with interferon alfa-2b in the US. The firm was founded by Donald J. Kerrish, Paul F. Fagan, and Patrick L. Kerrish in April, 2000 and is headquartered in Cranberry Township, PA. | Health Technology |
Guilford Pharmaceuticals, Inc.
Guilford Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Guilford Pharmaceuticals Inc. is a pharmaceutical company engaged in the research, development and commercialization of proprietary drugs that target the hospital and neurology markets. Presently, Guilford markets two commercial products, GLIADEL(R) Wafer, for the treatment of brain cancer, and AGGRASTAT(R) Injection, a glycoprotein GP IIb/IIIa receptor antagonist for the treatment of acute coronary syndrome (ACS). Guilford's product pipeline includes a novel anesthetic, AQUAVAN(R) Injection, and drugs for treating Parkinson's disease and peripheral nerve injury | Health Technology |
SEQUUS Pharmaceuticals, Inc.
SEQUUS Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology SEQUUS Pharmaceuticals, Inc. is based in Menlo Park, CA. Part of Johnson & Johnson, SEQUUS Pharmaceuticals, Inc. is a company that markets lipid-based biopharmaceutical products mainly to treat cancer and infectious diseases. SEQUUS Pharmaceuticals was acquired by ALZA Corp., part of Johnson & Johnson from June 22, 2001 on March 16, 1999 for $658.03 million. | Health Technology |
Cephalon, Inc.
Cephalon, Inc. Pharmaceuticals: MajorHealth Technology Cephalon, Inc. manufactures and distributes pharmaceutical products. It engages in the discovery and development of medicines for central nervous system disorders, pain, and cancer. The company was founded on August 24, 1987 by Frank Baldino, Jr. and is headquartered in Frazer, PA. | Health Technology |
